A Better Way to Grow Insulin-Producing Cells From Pigs for Transplant
Researchers have developed an improved method for culturing neonatal porcine islets that produces more functional insulin-secreting cells, potentially bringing pig-to-human pancreatic transplants closer to clinical reality.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- A dynamic bioreactor system produced significantly more insulin-producing beta cells and healthier islet tissue compared to traditional static culture methods
- Transplanted pig islets from the improved culture system normalized blood sugar faster in diabetic mice than islets grown the conventional way
- This advancement addresses a major barrier to xenotransplantation—the ability to produce enough high-quality insulin-producing cells at scale for human patients
- While promising, this research is in early stages and has only been tested in mice; human trials remain years away
The Challenge: Growing Enough Healthy Beta Cells
Type 1 diabetes destroys the beta cells in the pancreas that produce insulin, forcing people to rely on insulin injections for life. One potential solution is transplanting new beta cells into patients. Porcine (pig) islets are a promising source because pigs are physiologically similar to humans and can be bred specifically for medical use.
However, current methods for growing these pig islets in the laboratory don't produce enough cells reliably or in sufficient quantities for clinical use. Researchers have been working to solve this scalability problem—the ability to manufacture large numbers of high-quality beta cells consistently.
Testing a New Culture System
Scientists compared three different ways of culturing neonatal (newborn) pig islets: traditional static suspension and two versions of a dynamic bioreactor system called the PBS Mini Vertical-Wheel, operated at different cell densities (4.5K and 6.0K cells per milliliter).
The dynamic bioreactor at the higher density (Bio 6.0) produced substantially better results. It generated significantly more total DNA, higher insulin content, and greater recovery of functional beta cells compared to static culture. The islets were also smaller and better organized, with improved overall tissue quality.
What Happened in Transplanted Mice
To test whether the improved islets actually functioned better, researchers transplanted them into mice with streptozotocin-induced diabetes (a laboratory model of the disease). They compared islets grown using the new Bio 6.0 method against islets from traditional static culture.
Mice that received Bio 6.0 islets achieved faster normalization of blood sugar levels. The transplanted pig islets also demonstrated superior performance in metabolic function tests. When researchers examined the transplanted tissue after the experiment, they found the Bio 6.0 grafts had better structure and function.
What This Means—and What Remains Unknown
This research demonstrates that how beta cells are grown in the laboratory significantly affects how well they work after transplant. The dynamic bioreactor system appears to produce healthier, more functional islets that perform better when transplanted into recipients.
This is an important step toward making xenotransplantation a viable option for Type 1 diabetes patients. However, this work is still in early-stage research, tested only in mice. Many questions remain before human trials can begin: safety in humans, whether the immune system will reject pig cells even with immunosuppression, and how to scale this method for widespread clinical use. These results suggest the approach is worth pursuing further, but significant work lies ahead.
Evidence label
Source: Xenotransplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Our own writing on the same ground.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsGene-Edited Islets Show Promise, But Long-Term Questions RemainPubMed indexed literature
- Research summaryCure & AdvancementsHow Islet Size Shapes Cell Composition: What Scientists Found in Healthy PancreasesPubMed indexed literature
- Research summaryCure & AdvancementsStem Cell-Derived Islets: A New Research Path Toward Restoring Insulin ProductionPubMed indexed literature
- Research summaryCure & AdvancementsBerberine Shows Promise for Pancreatic Cell Recovery in Type 1 Diabetes ResearchPubMed indexed literature
- Research summaryCure & AdvancementsHow Gut Bacteria May Influence Type 1 Diabetes Risk Through Immune ControlPubMed indexed literature
- Research summaryCure & AdvancementsNew Blood Test May Help Identify Type 1 Diabetes EarlierPubMed indexed literature